Table 2.
Histological features of patients with NAFLD comparing elderly to non-elderly patients
Histological Feature* | Age Group
|
P† | |
---|---|---|---|
Non-elderly (N=735) No. (%) | Elderly (N=61) No. (%) | ||
Steatosis: | |||
Grade | 0.20 | ||
0–1 (0%–33%) | 309 (42.0%) | 31 (50.8%) | |
2 (>33%–66%) | 252 (34.3%) | 18 (29.5%) | |
3 (>66%) | 174 (23.7%) | 12 (19.7%) | |
Location (predominant) | 0.02 | ||
Zone 3 (central) | 307 (41.8%) | 15 (24.6%) | |
Zone 1(periportal) | 11 (1.5%) | 0 (0.0%) | |
Azonal | 195 (26.6%) | 26 (42.6%) | |
Panacinar | 221 (30.1%) | 20 (32.8%) | |
Microvesicular steatosis: present | 74 (10.1%) | 9 (14.8%) | 0.27 |
Fibrosis: | |||
Stage: | |||
None (0) | 200 (27.4%) | 5 (8.2%) | 0.001 |
Mild/moderate ( zone 3), portal/periportal (1A, 1B, 1C) | 209 (28.3%) | 13 (21.3%) | |
Zone 3 & periportal (2) | 141 (19.3%) | 16 (26.2%) | |
Bridging (3) | 122 (16.7%) | 19 (31.0%) | |
Cirrhosis (4) | 61 (8.3%) | 8 (13.1%) | |
Advanced fibrosis: | 0.002 | ||
None (0), mild (1), moderate (2) | 548 (75.0%) | 34 (55.7%) | |
Bridging (3) or cirrhosis (4) | 183 (25.0%) | 27 (44.3%) | |
Inflammation: | |||
Lobular inflammation (score) (no. foci per 200X field) | 0.007 | ||
0 to <2 foci (0–1) | 392 (53.3%) | 22 (36.1%) | |
2 to 4 foci (2) | 267 (36.3%) | 26 (42.6%) | |
>4 foci (3) | 76 (10.3%) | 13 (21.3%) | |
Microgranulomas: present | 603 (82.0%) | 52 (82.3%) | 0.60 |
Large lipogranulomas: present | 279 (38.0%) | 33 (54.1%) | 0.02 |
Portal Inflammation (score) | 0.23 | ||
None (0) | 111 (15.1%) | 5 (8.2%) | |
Mild (1) | 466 (63.4%) | 39 (63.9%) | |
More than mild (2) | 158 (21.5%) | 17 (27.9%) | |
Liver cell injury: | |||
Ballooning (score): | 0.004 | ||
None (0) | 251 (34.2%) | 15 (24.6%) | |
Few (1) | 199 (27.1%) | 9 (14.8%) | |
Many (2) | 285 (38.8%) | 37 (60.7%) | |
Acidophil bodies: many | 215 (29.3%) | 26 (42.6%) | 0.04 |
Pigmented macrophages: many | 644 (87.6%) | 54 (88.5%) | 1.00 |
Megamitochondria: many | 106 (14.4%) | 15 (24.6%) | 0.04 |
Other findings | |||
Mallory Denk bodies: many | 194 (26.4%) | 32 (52.5%) | < 0.001 |
Glycogenated nuclei: many | 392 (53.3%) | 29 (47.5%) | 0.42 |
NAFLD Activity Score (NAS) | 0.23 | ||
0 – 4 | 384 (52.2%) | 27 (44.3%) | |
5 – 8 | 351 (47.8%) | 34 (55.7%) | |
Mean ± SD | 4.38 ± 1.67 | 4.82 ± 1.69 | 0.05 |
Diagnostic classification: | |||
Steatohepatitis (diagnosis): | 0.12 | ||
Not steatohepatitis (0) | 166 (22.6%) | 10 (16.4%) | |
Possible/borderline: | |||
Zone 3 pattern (1A) | 148 (20.1%) | 7 (11.5%) | |
Zone 1, periportal (1B) | 9 (1.2%) | 0 (0.0%) | |
Definite steatohepatitis (2) | 412 (56.1%) | 44 (72.1%) | |
Definite NASH (yes) | 412 (56.1%) | 44 (72.1%) | 0.02 |
Determination of histological features from centrally reviewed biopsies using the NASH CRN Scoring System9
P values determined from Fisher’s exact test or Cuzick non-parametric test for trend across ordered categories, except for NAS, a t-test was used